Skip to main content

Free Content Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative

Download Article:
(PDF 100.2 kb)


Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.

Keywords: DOTS-Plus; MDR-TB; adverse events; second-line drugs

Document Type: Short Communication

Affiliations: 1: Stop TB Department, World Health Organization, Geneva, Switzerland 2: Socios En Salud, Lima, Peru 3: State Centre of Tuberculosis and Lung Diseases of Latvia, Riga, Latvia 4: MDR-TB Project in Tomsk Oblast, Partners in Health/Harvard Medical School, Tomsk, Russian Federation 5: Tropical Disease Foundation, Makati Medical Center, Manila, Philippines 6: Lung Clinic, Tartu University Clinics, Tartu, Estonia

Publication date: November 1, 2004

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more